Alain H. Rook, MD

Dermatology
Accepting new patients
Sees patients age 18 and up
Penn Dermatology Perelman
Schedule onlineCall 215-662-2737
Headshot of Alain H. Rook, MD
Penn Medicine Provider

About me

  • Director, Photopheresis Program
  • Professor of Dermatology

My education and training

  • Medical School: University of Michigan
  • Residency: McGill University
  • Residency: University of Pennsylvania Health System
  • Fellowship: McGill University
  • Fellowship: National Institutes of Health

Spoken languages

English
English
Français
French

Reviews

Average Rating

110 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
April 2026
expert. personable . great communicator
Anonymous
April 2026
i brag about him all the time, i have been his patient since 2014
Anonymous
April 2026
very knowledgeable and courteous
Anonymous
April 2026
the best!

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: On the medical staff, but does not have privileges to treat patients in the hospital.
Dr. Rook is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

Weiner DM, Clark AK, Bhansali RS, Pappas-Taffer L, Barta SK, Villasenor-Park J, Haun PL, Vittorio CC, Rook AH, Kim EJ, Samimi SS. Usage and safety of topical tacrolimus in patients with mycosis fungoides , Clin Exp Dermatol.: 2022

Nihal M, Wu J, Stonesifer CJ, Daniels J, Choi J, Geskin L, Rook AH, Wood GS. Epigenetic Regulation of Apoptosis in Cutaneous T-Cell Lymphoma: Implications for Therapy with Methotrexate, Jak Inhibitors, and Resveratrol , J Invest Dermatol. , 142(2): 2022,493-496

Lewis DJ, Rook AH. Combination therapies for mycosis fungoides/Sézary syndrome: biologic rationale and recommendations , Int J Dermatol., 60(9): 2021,e362-e364

Lewis DJ, Haun PL, Samimi SS, Vittorio CC, Villasenor-Park J, Barta SK, Landsburg DJ, Svoboda J, Nasta SD, Schuster SJ, Rook AH, Kim EJ. Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome , JAMA Dermatol. , 157(3): 2021,317-321

Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC Clinically significant responses achieved with romidespsin across disease compartments in patients with cutaneous T-cell lymphoma , Leuk Lymphoma : 2015,1-22

Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Waksman J, Whittaker S. Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. , Leuk Lymphoma, 20: 2015,1-22

Cedeno-Laurent F, Singer Em, Wysocka M, Benoit BM, Vittorio CC, Kim EJ, Yosipovitch G, Rook AH. Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. , Clin Immunol, 158(1): 2015,1-7

Spaccarelli N, Gharavi M, Saboury B, Cheng G, Rook AH, Alavi A. Role of (18)F-fluorodeoxyglucose positron emission tomography imaging in the management of primary cutaneous lymphomas. , Hell J Nucl Med, 17(2): 2014,78-84

Wysocka M, Kossenkov AV, Benoit BM, Troxel AB, Singer E, Schaffer A, Kim B, Dentchev T, Nagata S, Ise T, Showe LC, Rook AH. CD164 and FCRL3 are highly expressed on the CD4+CD26- T-cells in Sezary Syndrome patients. , J Invest Dermatol, 134: 2014,229-36

Samimi S, Chu E, Seykora J, Loren A, Vittorio C, Rook A, Rosenbach M, Kim EJ. Dasatinib-induced leukotrichia in a patient with chronic myelogenous leukemia. , JAMA Dermatol, 149(5): 2013